Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/22 CAR-T Cells in Relapsed/Refractory Leukemia/Lymphoma
NCT07162571Phase 2Enrolling by invitation
- Sponsor
- Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
- Start
- Oct 2026
- Primary completion
- Dec 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CAR19/22 T-cell cocktail therapy in acute lymphoblastic leukemia (ALL), B cell lymphoma, sponsored by Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology. Started Oct 2026; status: enrolling by invitation.
02
Drugs
CAR19/22 T-cell cocktail therapy
03
Conditions
acute lymphoblastic leukemia (ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT07162571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162571.